Group 1 - The core point of the article is that Zhaoyan New Drug (603127) announced a reduction in the shareholding plan of shareholders Gu Xiaolei and Gu Meifang from a maximum of 4.1026% to 3% of the company's total share capital, with the method of reduction changing to a combination of centralized bidding and block trading [1][1][1] - On March 16, Zhaoyan New Drug had previously announced that Gu Xiaolei and his concerted actor Gu Meifang intended to reduce their holdings by up to 4.1026% through centralized bidding, indicating a clearance-style reduction of A-share holdings [1][1][1] - Following this news, Zhaoyan New Drug's stock price hit the daily limit down on March 17 [1][1][1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2026年3月17日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫 雲 霞 女 士、羅 樨 女 士 及 顧 靜 良 先 生，獨 立 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2026-007 北京昭衍新药研究中心股份有限公司 关于股东减持 A 股股份计划公告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于 2026 年 3 月 17 日披露了《昭衍新药关于股东减持 A 股股份计划公告》（公告编号：2026-006）。 鉴于股东顾晓磊、顾美芳拟将合计减持比例由不超过占公司总股本的 4.1026%调 整为 3.00%，同时减持方式由集中竞价调整为集中竞价和大宗交易相结合的方式。 现对该公告进一步补充说明如下： 更正前： 减持计划的主要内容：股东顾晓磊及其一致行动人顾美芳拟自本减持计划公 告之日起 3 个交易日后的 3 个月内，通过上海证券交易所以集中竞价的方式分别 减持 20,420,504 股、10,322,035 股，合计减持 30,742,539 股，占公司当前总股本 的 4.1026%。减持计划实施期间，公司若发生送红股、转增股本、增发新股或配 股等股本除权事项的，减持 ...

Core Viewpoint - Shareholders Gu Xiaolei and Gu Meifang of Zhaoyan New Drug have revised their share reduction plan from a maximum of 30.7425 million shares, accounting for 4.1026% of the total share capital, to a maximum of 3.00% of the company's total share capital within three months after the announcement [1] Summary by Category Share Reduction Plan - Gu Xiaolei plans to reduce holdings through centralized bidding of up to 5.0206 million shares and block trading of up to 10.0412 million shares, totaling no more than 15.0618 million shares, which represents 2.01% of the total share capital [1] - Gu Meifang intends to reduce holdings through centralized bidding of up to 2.4728 million shares and block trading of up to 4.9456 million shares, totaling no more than 7.4184 million shares, which accounts for 0.99% of the total share capital [1] - The reduction period is set from March 20, 2026, to June 19, 2026 [1]

Core Viewpoint - The significant drop in the stock price of Zhaoyan New Drug is attributed to a large-scale share reduction announcement by major shareholders, leading to a market capitalization decline of over 20.53 billion yuan in a single day [1]. Group 1: Shareholder Actions - Major shareholders Gu Xiaolei and Gu Meifang plan to reduce their holdings by a total of 30.74 million shares, representing 4.1026% of the company's total share capital, from March 20, 2026, to June 19, 2026 [1]. - The reduction is primarily driven by personal financial needs, with the estimated value of the shares to be sold amounting to approximately 840 million yuan based on the closing price on March 16 [1]. - The Gu family, which has historical ties to the company, has been reducing their stakes since the company's IPO, with previous reductions noted in 2018 and 2022 [2][4]. Group 2: Company Performance - Zhaoyan New Drug's main business is underperforming, with a projected revenue decline of approximately 13.9% to 22.1% for 2025 compared to 2024, despite a significant increase in net profit [6]. - The expected net profit for 2025 is projected to be between 233 million and 349 million yuan, a substantial increase of 214% to 371% compared to 2024 [6]. - The increase in net profit is largely attributed to the appreciation of biological assets, particularly laboratory monkeys, which have seen a rebound in prices after a previous decline [7]. Group 3: Market Reactions - The stock market reacted negatively to the news of shareholder reductions, with Zhaoyan New Drug's stock price dropping by 10.01% to 29.32 yuan per share, reaching the daily limit down [1]. - The overall market sentiment appears to be influenced by the ongoing sell-off by major shareholders, leading to a loss of confidence among retail investors [8].

Summary of Key Points Core Viewpoint - On March 17, a total of 36 stocks were involved in institutional trading, with 17 stocks showing net buying and 19 stocks showing net selling by institutions [1]. Group 1: Institutional Net Buying - The top three stocks with the highest net buying by institutions were: - Langke Technology: Net buying amount of 231 million yuan, with a price increase of 11.62% [2]. - Xinghuan Technology: Net buying amount of 119 million yuan, with a price decrease of 20.00% [2]. - Xiangming Intelligent: Net buying amount of 77 million yuan, with a price increase of 20.01% [2]. - Other notable stocks with net buying included: - Shun Steel Co.: Net buying of 68.9 million yuan, with a price increase of 10.02% [2]. - Gude Electric Materials: Net buying of 66.3 million yuan, with a price increase of 20.00% [2]. Group 2: Institutional Net Selling - The top three stocks with the highest net selling by institutions were: - Zhaoyan Pharmaceutical: Net selling amount of 202 million yuan, with a price decrease of 10.01% [3]. - Zhongci Electronics: Net selling amount of 76.2 million yuan, with a price decrease of 9.94% [3]. - Zhongfu Shenying: Net selling amount of 67.8 million yuan, with a price increase of 20.00% [3]. - Other notable stocks with net selling included: - Jiamai Packaging: Net selling of 126.8 million yuan, with a price increase of 3.42% [3]. - Xinyaya Cable: Net selling of 356.6 million yuan, with a price increase of 4.37% [3].

Group 1 - The company Zhaoyan New Drug experienced a limit down on March 17, with a trading volume of 855 million yuan and a turnover rate of 4.57% [1] - The Shanghai Stock Connect special seat bought 36.01 million yuan and sold 38.70 million yuan, indicating a net sell-off [1] - Four institutional special seats had a net sell of 202 million yuan, reflecting a significant withdrawal from the stock [1]

Group 1 - The article highlights the formation of a MACD golden cross signal, indicating a positive trend for certain stocks [1][2] - It emphasizes the importance of timely and comprehensive analysis for identifying potential investment opportunities [1][2] Group 2 - The source of the information is Shenzhen Commercial Daily, and it is noted that the content is a reprint from a cooperative media outlet [1][2] - The article does not provide specific stock recommendations or investment advice, serving only as informational content [1][2]

Core Viewpoint - The stock price of Zhaoyan New Drug fell sharply due to a significant share reduction plan by major shareholders, which exceeded market expectations [3][4]. Shareholder Reduction Plan - Shareholders Gu Xiaolei and Gu Meifang plan to reduce their holdings by approximately 30.74 million shares, accounting for 4.1026% of the company's total share capital [4]. - The reduction will occur over three months, starting three trading days after the announcement [4]. - Gu Xiaolei and Gu Meifang hold approximately 20.42 million shares (2.7251%) and 10.32 million shares (1.3775%) respectively, and their reduction will not change the company's control [4]. Previous Shareholder Actions - The actual controller Zhou Zhiwen previously announced a reduction plan to sell up to 14.98 million shares, which is 20.0466% of his holdings, but he terminated the plan early after selling 14.979 million shares [5]. Financial Performance Expectations - Zhaoyan New Drug expects a revenue decline of 13.9% to 22.1% in 2025, projecting revenues between 1.573 billion to 1.738 billion yuan [8]. - The company anticipates a significant increase in net profit, forecasting a rise of 214% to 371%, with net profit expected to be between 233 million to 349 million yuan [8]. - The increase in net profit is largely attributed to the fair value changes of biological assets, particularly the rising prices of monkeys used in experiments [8][9]. Market Demand and Asset Valuation - There is a strong demand for experimental monkeys in clinical trials, leading to increased interest from various companies in this sector [9]. - The valuation of experimental monkeys is subject to significant fluctuations, raising questions about the sustainability of Zhaoyan New Drug's investment logic [9].

Core Viewpoint - The AI healthcare sector experienced a decline of 1.19% on March 17, with Zhaoyan New Drug leading the drop [1] Market Performance - The Shanghai Composite Index closed at 4049.91, down 0.85% [1] - The Shenzhen Component Index closed at 14039.73, down 1.87% [1] Capital Flow - The AI healthcare sector saw a net outflow of 1.315 billion yuan from main funds, while retail investors contributed a net inflow of 1.263 billion yuan [1] - Speculative funds recorded a net inflow of 51.964 million yuan [1]